Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Aranesp study shows no difference in survival in patients with SCLC

April 24, 2007

NDA filing for fixed-dose Niaspan/simvastatin tablet

April 23, 2007

De Novo designs novel inhibitors for 11beta-hydroxysteroid dehydrogenase

April 23, 2007

Recent Pfizer patent claims novel therapeutic agents for thrombocytopenia

April 23, 2007

Ostarine improves insulin resistance in elderly patients

April 20, 2007

Zenvia improves pain rating scale in painful diabetic neuropathy

April 20, 2007

Sciele studies pravastatin and fenofibrate combination in phase II

April 20, 2007

Protalix cleared to begin phase III study of prGCD for Gaucher's disease

April 20, 2007

Enrollment completed for phase II osteoporosis study of NB-S101

April 20, 2007

Recent patents disclose novel agents for obesity and metabolic disorders

April 20, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...